| Biotechnology Industry | Healthcare Sector | Dr. Paul F. McKenzie Ph.D. CEO | XDUS Exchange | US12637N2045 ISIN |
| Australia Country | 32,698 Employees | 11 Mar 2025 Last Dividend | - Last Split | - IPO Date |
CSL Limited is a globally recognized biopharmaceutical company with a rich history dating back to 1916. Headquartered in Melbourne, Australia, CSL Limited has expanded its operations across major global markets including Australia, the United States, Germany, the United Kingdom, Switzerland, China, and Hong Kong. The company's mission is to research, develop, manufacture, market, and distribute a wide range of biopharmaceutical products and vaccines. CSL Limited operates through three main segments: CSL Behring, CSL Seqirus, and CSL Vifor, each focusing on different areas of healthcare. In addition to its product offerings, CSL Limited actively engages in licensing its intellectual property, further demonstrating its commitment to advancing healthcare and innovation.
This segment is specialized in providing a comprehensive range of plasma products, gene therapies, and recombinants. CSL Behring focuses on developing treatments for rare and serious diseases, leveraging the power of science to create new possibilities for patients.
CSL Seqirus is dedicated to addressing public health challenges related to influenza. The segment is a leading provider of influenza vaccines and offers pandemic services to governments worldwide. Its focus on innovation and preparedness plays a crucial role in global health security.
Focused on the therapeutic areas of iron deficiency and nephrology, CSL Vifor brings specialized products to patients suffering from these conditions. The segment aims to improve the quality of life for people with chronic kidney disease and iron deficiency anemia by providing innovative treatment options.